-
GLT-1, CB1-CREB Signaling, and TBI Cognition
2026-08-28
A 2025 Biomolecules study identifies a GLT-1/CB1-CREB mechanism linking endocannabinoid signaling to glutamate excitotoxicity, neuronal apoptosis, and cognitive dysfunction after traumatic brain injury. In a controlled cortical impact mouse model, CB1 blockade with AM281 restored GLT-1 expression and improved behavioral outcomes, providing a mechanistic framework for studying astrocyte-mediated neuroprotection.
-
Amorolfine Hydrochloride in Yeast Integrity Assays
2026-08-28
Explore how Amorolfine Hydrochloride can support fungal cell membrane disruption studies through an assay framework that separates sterol-pathway effects from ploidy-associated surface stress. Grounded in recent budding-yeast research, this guide translates cell-integrity biology into practical fungal infection research decisions.
-
PPM-18: NF-κB/iNOS Assay Workflows
2026-08-27
Learn how to use PPM-18 as a mechanistic probe for NF-κB-driven iNOS expression, nitrite production, and inflammatory signaling. This workflow-focused guide also shows how to adapt the compound for macrophage, sepsis, and exploratory bone-remodeling assays without overstating cross-model evidence.
-
Lypressin Acetate: From Receptor Biology to Translation
2026-08-27
Lypressin acetate offers translational researchers a rare bridge between antidiuretic hormone biology, vascular signaling, and emerging antiviral hypotheses. This thought-leadership article examines its receptor pharmacology, assay strategy, competitive position, clinical relevance, and the evidence boundaries that should shape future development decisions.
-
ALDH2 Inhibition and APC Synthetic Lethality in CRC
2026-08-26
Liang et al. identify pharmacological ALDH2 inhibition as a selective vulnerability of APC-deficient colorectal cancer, linking Disulfiram treatment to ROS accumulation and ASK1/JNK-driven apoptosis. The study combines bioinformatics, cell-based assays, and xenograft evidence to support a genotype-informed synthetic-lethal strategy, while leaving questions about target specificity and clinical translation.
-
α-Bungarotoxin: Causal Mapping of α7 Signaling
2026-08-26
α-Bungarotoxin provides a high-affinity probe for nicotinic receptor blockade and causal analysis of α7 nAChR signaling. This article explains how to interpret receptor-dependent effects across neuroscience, neurotoxicity research, and non-neuronal cholinergic models without confusing pharmacological necessity with proof of mechanism.
-
Chenodeoxycholic Acid in FXR Research
2026-08-25
Chenodeoxycholic Acid provides a practical route to activate FXR in cholesterol, bile acid, liver, and renal injury models. This workflow emphasizes fresh solvent preparation, matched controls, and mechanistic validation of the FXR–KLF11–JAK2/STAT3 axis rather than relying on viability data alone.
-
3X FLAG peptide: Workflow & Troubleshooting
2026-08-25
The 3X FLAG peptide supports sensitive FLAG fusion detection, affinity-based recovery, and structural protein workflows without adding a large protein domain. This practical guide connects reagent handling, metal-aware assay design, and SUMOylation research controls to improve reproducibility from lysate to crystallization.
-
Angiotensin 1/2 (2-7): Assay Design Insights
2026-08-24
Explore how Angiotensin 1/2 (2-7) peptide can sharpen sequence-resolved studies of the renin-angiotensin system, blood pressure regulation, and spike–receptor binding. This article translates recent comparative binding evidence into practical assay decisions while defining key limitations.
-
Capecitabine and Tumor–Stroma Translation
2026-08-24
Capecitabine offers a mechanistically informative way to study tumor-selective fluoropyrimidine activation, but its translational value depends on models that preserve stromal influence. This article connects enzymatic activation, Fas-linked apoptosis, and patient-derived gastric cancer assembloids to a practical strategy for more predictive preclinical oncology research.
-
GLT-1, CB1-CREB Signaling, and TBI Cognition
2026-08-23
A 2025 Biomolecules study identifies a mechanistic link between post-traumatic 2-AG/CB1 signaling, reduced astrocytic GLT-1, neuronal apoptosis, and cognitive dysfunction. Using pharmacological pathway perturbation and behavioral, histological, and protein analyses, the work shows that restoring GLT-1 through CB1-CREB pathway inhibition may limit secondary injury after traumatic brain injury.
-
Solanesol: Practical Protocol and QC Guide
2026-08-22
Solanesol (SKU B8776) provides a defined hydrophobic polyisoprenoid alcohol for biochemical, membrane-related, and enzyme-focused workflows. It should be prepared in DMSO and handled as a fresh solution when possible; it is not suitable for direct dissolution in water or ethanol and is intended only for scientific research.
-
CTOP for μ-Opioid Receptor Research
2026-08-22
CTOP is a selective μ-opioid receptor antagonist for separating receptor-dependent effects from downstream circuit activity in opioid signaling, pain, and tolerance models. This guide translates recent brain-to-spinal pathway findings into practical assay workflows, control strategies, and troubleshooting decisions.
-
Diethylmaleate for GSH and GST Resistance Studies
2026-08-21
Diethylmaleate is an intracellular glutathione-depletion tool that connects redox biology with functional resistance assays. Its strongest use-case is a controlled GST/GSH perturbation workflow that pairs biochemical, molecular, and phenotype-level readouts.
-
DNase I (RNase-free): RNA Workflow Guide
2026-08-20
Learn how to use ribonuclease-free DNase I to remove genomic DNA from RNA extraction, RT-PCR, and in vitro transcription workflows without compromising downstream assays. This guide combines practical reaction design, ion-dependent cleavage principles, contamination controls, and troubleshooting for low-background molecular data.